Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and CommercializationGuruFocus · 1 day ago
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialGuruFocus · 5 days ago
Micot Pharma Debuts MT200605 Huntington's Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative DiseasesGuruFocus · Oct 12, 2026
5 ETF Areas That Have Nearly Doubled in First Nine Months of 2026Zacks Investment Research · Sep 24, 2026
The VistaShares Artificial Intelligence Supercycle® ETF (AIS) Hits $1 Billion in AssetsGlobeNewsWire · Sep 15, 2026
Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026GuruFocus · Aug 31, 2026This actively managed exchange-traded fund (ETF) is designed to achieve its investment objective by strategically allocating capital to a diversified portfolio of artificial intelligence (AI) companies across the globe. The sub-adviser's strategy is to manage the fund's assets in pursuit of returns that mirror those of the BITA VistaShares Artificial Intelligence Supercycle Index. Under typical market conditions, the fund commits a minimum of 80% of its net assets, including any funds borrowed for investment, to AI-focused enterprises.